These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa]. Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa. Mitsugui CS; Tognim MC; Cardoso CL; Carrara-Marroni FE; Botelho Garcia L Int J Antimicrob Agents; 2011 Nov; 38(5):447-50. PubMed ID: 21872449 [TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759 [TBL] [Abstract][Full Text] [Related]
25. In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran. Malekzadegan Y; Abdi A; Heidari H; Moradi M; Rastegar E; Sedigh Ebrahim-Saraie H BMC Res Notes; 2019 May; 12(1):301. PubMed ID: 31138309 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005. Babay HA Jpn J Infect Dis; 2007 May; 60(2-3):123-5. PubMed ID: 17515646 [TBL] [Abstract][Full Text] [Related]
27. oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides. Wang H; Meng J; Jia M; Ma X; He G; Yu J; Wang R; Bai H; Hou Z; Luo X FEMS Immunol Med Microbiol; 2010 Dec; 60(3):275-82. PubMed ID: 20955466 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Etest method for detecting colistin susceptibility of multidrug-resistant Gram-negative isolates in Vietnam. Nhung PH; Miyoshi-Akiyama T; Phuong DM; Shimada K; Anh NQ; Binh NG; Thanh do V; Ohmagari N; Kirikae T J Infect Chemother; 2015 Aug; 21(8):617-9. PubMed ID: 25960156 [TBL] [Abstract][Full Text] [Related]
30. Highly Synergistic Effects of Melittin with Conventional Antibiotics Against Multidrug-Resistant Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. Akbari R; Hakemi-Vala M; Pashaie F; Bevalian P; Hashemi A; Pooshang Bagheri K Microb Drug Resist; 2019 Mar; 25(2):193-202. PubMed ID: 30281385 [TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa. Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502 [TBL] [Abstract][Full Text] [Related]
32. Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy. Borgatta B; Lagunes L; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1097-1104. PubMed ID: 28093651 [TBL] [Abstract][Full Text] [Related]
33. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058 [TBL] [Abstract][Full Text] [Related]
34. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767 [TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea. Lee YC; Ahn BJ; Jin JS; Kim JU; Lee SH; Song DY; Lee WK; Lee JC J Microbiol; 2007 Aug; 45(4):358-63. PubMed ID: 17846591 [TBL] [Abstract][Full Text] [Related]
36. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Güzel CB; Gerçeker AA Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan. Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693 [TBL] [Abstract][Full Text] [Related]
38. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus]. Cetinkaya E; Coban AY; Durupinar B Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076 [TBL] [Abstract][Full Text] [Related]
39. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. Milne KE; Gould IM J Antimicrob Chemother; 2010 Jan; 65(1):82-90. PubMed ID: 19861334 [TBL] [Abstract][Full Text] [Related]
40. Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey. Işeri L; Bayraktar MR New Microbiol; 2008 Jul; 31(3):351-5. PubMed ID: 18843889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]